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treating only the wt KRAS patients with panitumumab was €4.9
million, resulting in 41.7% savings. Total cost ﬁgures for the
private sector were €8.7 million and €5 million respectively,
resulting in 42.5% savings. CONCLUSIONS: By identifying the
wt KRAS patients who are most likely to respond to treatment,
panitumumab improves treatment outcomes and reduces unnec-
essary exposure to therapy, resulting in overall budget savings.
Patient-level clinical beneﬁts derived by panitumumab may lead
to improvements in health outcomes and rational allocation of
health care resources in Greece.
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OBJECTIVES: A molecular assay (GeneSearch™ Breast Lymph
Node (BLN) Assay, Veridex, LLC), CE marked and approved by
the FDA, has been in clinical use at our institution for over 18
months to intra-operatively detect metastases 30.2 mm in the
sentinel lymph nodes (SLNs) of breast cancer patients. After a
small validation study (N = 78, sensitivity = 92.3%, speciﬁc-
ity = 96.9%) the assay was adopted as the only intra-operative
SLN test used at the Institut Jules Bordet. This is the ﬁrst evalu-
ation of the cost savings generated by the use of this BLN assay.
METHODS: An economic evaluation was conducted in the ﬁrst
300 patients in whom this BLN assay was used intra-operatively.
The BLN assay results are used to make intra-operative decisions
for axillary lymph node dissections (ALND) during the same
surgery. We assessed the pathology, surgery & anesthesia, phar-
macy, post-hospitalization, general, and total costs associated
with patients having either: Surgery A = a lumpectomy +
SLN + secondary ALND versus having: Surgery B = a
lumpectomy + BLN + ALND. RESULTS: The total costs per
patient for Surgery A was €3120, while for Surgery B it was
€2210. Therefore, a difference of €910, were saved per patient
when using the BLN assay, which represents a 29% cost savings.
Since 58 patients avoided having a second surgery, the total cost
savings accrued by the institution for the Belgian social security
system as a result of using the BLN assay in this ﬁrst cohort of
300 patients, was €52,780. CONCLUSIONS: The BLN assay
was proved to be beneﬁcial not only for our patients by reducing
the need of second surgeries, it has also been demonstrated to be
cost saving for the Belgian social security system. Its use at the
Institut Jules Bordet in the ﬁrst cohort of 300 patients has
resulted in a cost savings of €52,780.
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OBJECTIVES: To estimate the cost effectiveness of the addition
of cetuximab to chemotherapy in 1st-line metastatic colorectal
cancer (mCRC) from the UK NHS perspective. METHODS:
Cetuximab is licensed for the treatment of mCRC in combination
with chemotherapy (FOLFIRI and FOLFOX) in patients with
wildtype KRAS and EGFR expressing tumours. A Markov model
was developed to simulate disease progression, survival and
potential for curative surgery. Progression-free survival data were
extrapolated in the basecase analysis, utilising different paramet-
ric models. The potential for curative-intent liver surgery is esti-
mated from Folprecht et al. [1] which demonstrated correlation
between response rates to chemotherapy and resection rates.
Base case resection rates (active/comparator) of 22%/12%
(FOLFIRI) and 15%/7% (FOLFOX) were assumed using this
correlation. The long-term beneﬁts of surgery were estimated
from Adam et al [2]. Treatment in specialised centres may lead to
vial sharing and higher resection rates (55%/35% and 42%/26%
respectively), these assumptions are tested in sensitivity analysis.
The 1st line utility value (0.77) in the model was derived from
EQ5D data collected in the FOLFIRI trial. RESULTS: In the
basecase the addition of cetuximab to FOLFIRI/FOLFOX
resulted in: incremental life years gained of 0.358 and 0.413;
additional QALYs of 0.281 and 0.320; incremental cost effec-
tiveness ratios (ICERs) of £69,287 and £63,245 per QALY and
ICERs in specialised centres of £34,646 and £40,529. The ICER
is mainly driven by the number of patients becoming resectable
the acquisition cost of cetuximab, and parameterisation of the
progression-free survival curves. CONCLUSIONS: The analysis
demonstrates the role of cetuximab in enabling curative surgery
which drives the cost-effectiveness. When assessing a highly
selected group of patients within a subset with wild-type KRAS,
the ICERs are close to UK willingness to pay acceptance thresh-
olds. [1] Folprecht G, Grothey A, Alberts S et al, Neoadjuvant
treatment of unresectable colorectal liver metastases: correlation
between tumour response and resection rates. Ann Oncol
2005;16:1311–9; [2] Adam R et al, Rescue Surgery for Unresec-
table Colorectal Liver Metastases Downstaged by Chemo-
therapy. A Model to Predict Long-term Survival. Ann Surgery
2004;240.
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OBJECTIVES: To evaluate the cost-effectiveness of standard che-
motherapy plus adjuvant trastuzumab treatment for one year
compared to standard chemotherapy in patients with early breast
cancer in Saudi Arabia. METHODS: A Markov model was
adapted to estimate the costs and clinical outcomes (quality-
adjusted life-years (QALYs) and life expectancy) associated with
the progression of early breast cancer over patients’ lifetimes.
Patients transitioned through ﬁve health states according to
probabilities reﬂecting the rates of disease progression observed
in the HERA (HERceptin Adjuvant) trial. Total health care
resource costs and utilization were estimated for each health state
using values derived from a Saudi Arabian-speciﬁc survey. The
analysis was done from the perspectives of the health care pro-
vider and society. The mean starting treatment age was assumed
to be 30 years old, reﬂecting local demographics. Costs and
outcomes were discounted at 3.5% per annum. Sensitivity analy-
ses were performed. RESULTS: One-year adjuvant treatment
with trastuzumab was estimated to increase life expectancy by
2.4 (4.9 undiscounted) years and quality-adjusted life years by
2.2 (4.3 undiscounted) QALYs, compared to standard chemo-
therapy. Over a patient’s lifetime, total direct medical costs,
including indirect costs (attributed to travel and time off work for
patients and care-givers), were projected to increase by approxi-
mately SR48,452 (US$12,903) compared to chemotherapy
alone. Treatment with trastuzumab was estimated to partially
offset mean event and state costs compared to chemotherapy
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